TARIS Biomedical

Uro Pipeline: FDA accepts priority review application for RCC treatmentAgents for bladder cancer, prostate cancer, and stress urinary incontinence are also included in this round-up of pipeline developments.
Uro Pipeline: FDA committee votes in favor of nocturia treatment approvalOther pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
The future of drug delivery in the bladder?
Uro Pipeline: Bladder Ca drug-device combination begins second phase Ib trialA bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.
Urology Product Preview November 2013Urology drugs and devices in the pipeline from AltheRx Pharmaceuticals, TARIS Biomedical, AstraZeneca, NxThera, NovaBay Pharmaceuticals, and OncoGenex Pharmaceuticals.
Urology Product PreviewDrugs and devices in the pipeline from Medivation, Inc.; Astellas Pharma Inc.; TARIS Biomedical; Exelixis, Inc.; and Bioniche Life Sciences Inc.